Evaluating T3 as a treatment for medulloblastoma in children
Assessment of Efficacy and Toxicity of T3 for Medulloblastoma Treatment
This study is looking at whether a thyroid hormone called T3 can help treat medulloblastoma, a common brain tumor in kids, by seeing how it works alongside regular treatments like chemotherapy and radiation, with hopes of finding safer and better options for young patients in the future.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11034598 on NIH RePORTER |
What this research studies
This research investigates the use of T3, an FDA-approved thyroid hormone, as a potential treatment for medulloblastoma, the most common malignant brain tumor in children. The study aims to assess the safety and effectiveness of T3 in combination with traditional therapies like chemotherapy and radiation. By conducting experiments in mice, the researchers will evaluate how T3 affects tumor growth and its side effects, with the goal of providing essential data for future clinical trials in children. If successful, this research could lead to improved treatment options that minimize long-term side effects for young patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 10 years old diagnosed with medulloblastoma.
Not a fit: Patients with medulloblastoma who are older than 10 years or those who have already undergone extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for children with medulloblastoma, potentially reducing long-term side effects associated with current therapies.
How similar studies have performed: While the use of T3 in this context is novel, previous studies have shown promise in using similar approaches for other types of cancers.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Yang, Zeng-Jie — Research Inst of Fox Chase Can Ctr
- Study coordinator: Yang, Zeng-Jie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.